Cardiac myosin inhibitors: a silver lining for an old disease [PDF]
Open HeartSandeep Singh +2 more
doaj +4 more sources
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects [PDF]
Drug Design, Development and TherapyHypertrophic cardiomyopathy (HCM) is a common inherited disease with substantial residual morbidity despite established pharmacological and surgical therapies. We conducted a narrative review of the current evidence on cardiac myosin inhibitors, drawing on published studies up to July 2025, including pivotal clinical trials, real-world cohorts, and ...
Hou L, Lin B, Ji X, Huang A.
exaly +5 more sources
Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis [PDF]
Reviews in Cardiovascular MedicineBackground: Recent advancements have introduced novel cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in treating hypertrophic cardiomyopathy (HCM).
Yang Lu, Yuanyuan Zhu, Zhuang Tian
doaj +2 more sources
Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM
Journal of Education, Health and SportBackground: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka +3 more
doaj +2 more sources
Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]
J Cardiovasc ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim J, Kim HK.
europepmc +3 more sources
Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach [PDF]
Cardiovascular UltrasoundBackground Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and is characterized by unexplained myocardial hypertrophy. This condition exhibits marked clinical and prognostic heterogeneity.
Eluisa La Franca +10 more
doaj +2 more sources
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]
Int J Mol SciHypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
Nakamura K +7 more
europepmc +5 more sources
Cardiac myosin inhibitors in hypertrophic cardiomyopathy: advancing care with caution. [PDF]
Ann Med Surg (Lond)Rehman Z +4 more
europepmc +3 more sources
Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
Frontiers in Physiology, 2022 Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana +3 more
doaj +1 more source
Scientific Reports, 2023 Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe +11 more
doaj +1 more source